ANVS - NYSE
Annovis Bio, Inc.
$2.60
+0.78%Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
At a Glance
Live SnapshotAnnovis Bio, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Annovis Bio, Inc. Balance Sheet
ANVS • NYSE
| Annovis Bio, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
CURRENT ASSETS | |||||||||
19.5B | 10.6M | 5.8M | 28.4M | 45.7M | 8.1M | 1.9K | 35.3K | 347.5K | |
19.5B | 10.6M | 5.8M | 28.4M | 45.7M | 8.1M | 1.9K | 35.3K | 347.5K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 735.1K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 735.1K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -745.6M | 0.0 | 0.0 | |
0.0 | 3.4M | 4.4M | 104.9K | 305.6K | 38.2K | 4.1K | 11.9K | 6.7K | |
0.0 | 7.5K | 20.8K | 7.5M | 9.9K | 6.4K | 745.6M | 0.0 | 0.0 | |
19.5B | 13.9M | 10.2M | 36M | 46M | 8.1M | 747.5K | 51K | 358K | |
NON-CURRENT ASSETS | |||||||||
1.5B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 369.6K | 0.0 | 0.0 | |
1.5B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 369.6K | 0.0 | 0.0 | |
21.1B | 13.9M | 10.2M | 36M | 46M | 8.1M | 1.1M | 51K | 358K | |
LIABILITIES | |||||||||
CURRENT LIABILITIES | |||||||||
2.6M | 2.3M | 1.3M | 4M | 688.1K | 341.9K | 1.2M | 68.4K | 71.1K | |
2.6M | 2.3M | 1.3M | 4M | 688.1K | 341.9K | 1.2M | 68.4K | 71.1K | |
0.0 | 364.7K | 3M | 3.7M | 712.8K | 16.5K | 131.5K | 21.6K | 3.8K | |
3.6B | 1.2M | 273.0 | 0.0 | 105.7K | 220K | 645.3K | 477.9K | 415.3K | |
3.6B | 3.9M | 4.3M | 7.7M | 1.5M | 578.4K | 2M | 567.9K | 490.2K | |
NON-CURRENT LIABILITIES | |||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 499.8K | 0.0 | 0.0 | |
595M | 737K | 13.7M | 0.0 | 0.0 | 0.0 | 7.2M | 7.1M | 6.8M | |
595M | 737K | 13.7M | 0.0 | 0.0 | 0.0 | 7.7M | 7.1M | 6.8M | |
4.2B | 4.6M | 18M | 7.7M | 1.5M | 578.4K | 9.7M | 7.6M | 7.3M | |
SHAREHOLDERS' EQUITY | |||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.9M | 6.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1M | 7.1M | 6.8M | |
2.7K | 1.4K | 1.1K | 816.0 | 810.0 | 689.0 | 0.0 | 0.0 | 0.0 | |
180.6M | 144.2M | 102.5M | 82.4M | 73.2M | 21.8M | 200.6K | 192.1K | 106.6K | |
-163.7M | -134.8M | -110.3M | -54.1M | -28.7M | -14.2M | -8.8M | -7.8M | -7.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7.1M | -7.1M | -6.8M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1M | 6.8M | |
16.9B | 9.3M | -7.8M | 28.3M | 44.5M | 7.5M | -8.6M | -7.6M | -7M | |
16.9B | 9.3M | -7.8M | 28.3M | 44.5M | 7.5M | -8.6M | -7.6M | -7M | |
SUMMARY | |||||||||
21.1B | 13.9M | 10.2M | 36M | 46M | 8.1M | 1.1M | 51K | 358K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 499.8K | 0.0 | 0.0 | |
-19.5B | -10.6M | -5.8M | -28.4M | -45.7M | -8.1M | 497.9K | -35.3K | -347.5K | |
19,673,615 | 19,673,615 | 19,673,615 | 19,673,615 | 19,673,615 | 19,673,615 | 19,673,615 | 19,673,615 | 19,673,615 |
SEC Filings
ANVS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 28, 2026 | January 28, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 26, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 14, 2025 | October 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 25, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 15, 2025 | August 11, 2025 | 2025 |
Related Guides
Continue your ANVS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.